Suki, M.; Amer, J.; Milgrom, Y.; Massarwa, M.; Hazou, W.; Tiram, Y.; Perzon, O.; Sharif, Y.; Sackran, J.; Alon, R.;
et al. Semaglutide in MASLD Patients: Improved Survival and Liver Outcomes. Pharmaceuticals 2025, 18, 1075.
https://doi.org/10.3390/ph18071075
AMA Style
Suki M, Amer J, Milgrom Y, Massarwa M, Hazou W, Tiram Y, Perzon O, Sharif Y, Sackran J, Alon R,
et al. Semaglutide in MASLD Patients: Improved Survival and Liver Outcomes. Pharmaceuticals. 2025; 18(7):1075.
https://doi.org/10.3390/ph18071075
Chicago/Turabian Style
Suki, Mohamad, Johnny Amer, Yael Milgrom, Muhammad Massarwa, Wadi Hazou, Yariv Tiram, Ofer Perzon, Yousra Sharif, Joseph Sackran, Revital Alon,
and et al. 2025. "Semaglutide in MASLD Patients: Improved Survival and Liver Outcomes" Pharmaceuticals 18, no. 7: 1075.
https://doi.org/10.3390/ph18071075
APA Style
Suki, M., Amer, J., Milgrom, Y., Massarwa, M., Hazou, W., Tiram, Y., Perzon, O., Sharif, Y., Sackran, J., Alon, R., Lourie, N. E. E., Raz, I., Imam, A., Khalaileh, A., & Safadi, R.
(2025). Semaglutide in MASLD Patients: Improved Survival and Liver Outcomes. Pharmaceuticals, 18(7), 1075.
https://doi.org/10.3390/ph18071075
